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Abstract
Rheumatoid arthritis (RA) is an inflammatory autoimmune disease with no known cure. Current 
strategies to treat RA, including methotrexate (MTX), target the later inflammatory stage of 
disease. Recently, we showed that inhibiting indoleamine-2,3-dioxygenase (IDO) with 1-methyl-
tryptophan (1MT) targets autoantibodies and cytokines that drive the initiation of the autoimmune 
response. Therefore, we hypothesized that combining 1MT with MTX would target both the 
initiation and chronic inflammatory phases of the autoimmune response and be an effective co-
therapeutic strategy for arthritis. To test this, we used K/BxN mice, a pre-clinical model of 
arthritis that develops joint-specific inflammation with many characteristics of human RA. Mice 
were treated with 1MT, MTX, alone or in combination, and followed for arthritis, autoantibodies, 
and inflammatory cytokines. Both 1MT and MTX were able to partially inhibit arthritis when used 
individually; however, combining MTX + 1MT was significantly more effective than either 
treatment alone at delaying the onset and alleviating the severity of joint inflammation. We went 
on to show that combination of MTX + 1MT did not lower inflammatory cytokine or autoantibody 
levels, nor could the synergistic co-therapeutic effect be reversed by the adenosine receptor 
antagonist theophylline or be mimicked by inhibition of polyamine synthesis. However, 
supplementation with folinic acid did reverse the synergistic co-therapeutic effect, demonstrating 
that, in the K/BxN model, MTX synergizes with 1MT by blocking folate metabolism. These data 
suggest that pharmacological inhibition of IDO with 1MT is a potential candidate for use in 
combination with MTX to increase its efficacy in the treatment of RA.
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Introduction
Rheumatoid arthritis (RA) is an inflammatory autoimmune disease characterized by severe 
inflammation of cartilage and bone (1). Disease in RA patients is chronic and progressive 
and there is no known cure. Currently, four basic types of drugs are used to treat RA; non-
steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, disease-modifying anti-
rheumatic drugs (DMARDs), and biologic response modifying drugs (2–4). Often, these 
drugs are used in combination in an effort to increase their efficacy (5, 6). While these drugs 
help alleviate the symptoms of RA, there remains an urgent need for new therapeutic 
strategies to address the underlying causes that drive disease in RA patients.
Results from our laboratory suggest that the tryptophan catabolizing enzyme, 
indoleamine-2,3-dioxygenase (IDO) is a potential new therapeutic target in the treatment of 
RA (7, 8). IDO has been linked to immune modulation in a variety of disease settings, 
including tumor immunology and inflammatory autoimmune disease (9–11). The chief 
functional paradigm has been that IDO acts by suppressing T cell activation, prompting the 
general assumption that IDO inhibition would exacerbate autoimmune disorders (12, 13). 
However, studies using preclinical models of RA, asthma, and allergy suggest that the IDO 
pathway instead drives inflammation in certain pathological settings (7, 14, 15). 
Furthermore, RA patients exhibit elevated levels tryptophan catabolism that correlate with 
disease severity, suggesting that IDO may also contribute to pathogenicity in RA patients 
(16, 17).
To study the role of IDO in inflammatory autoimmune disease, we made use of 1-methyl-
tryptophan (1MT), a small molecule inhibitor of the IDO pathway together with the K/BxN 
preclinical model of arthritis (7). K/BxN mice share many similarities with RA patients, 
including high titers of autoantibodies, inflammatory cytokine production, and immune-
mediated destruction of cartilage and bone in the synovial joints (18, 19). Joint inflammatory 
disease develops spontaneously in 100% of K/BxN mice starting around 4 weeks of age and 
continues chronically throughout the life of the animal. As such, the K/BxN model has been 
useful for testing therapeutics designed either to prevent the onset or reverse the symptoms 
of ongoing disease (8, 20–22). Previously, we showed that treatment of K/BxN mice with 
1MT reduced autoantibody and inflammatory cytokine levels, resulting in an amelioration of 
arthritis symptoms (7). We further demonstrated that IDO was necessary for the 
differentiation of autoreactive B cells into antibody secreting cells, but not for their initial 
activation or maturation in germinal centers (8). These data demonstrated that IDO is 
important during the early stages of the autoimmune response, and as such, inhibitors of 
IDO will be most useful when administered at the initiation of the autoimmune response. In 
support of this, we recently showed that 1MT is effective at inhibiting the reactivation of 
autoreactive B cells following their regeneration after B cell depletion therapy (8).
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Currently, the most commonly used DMARD in RA patients is methotrexate (MTX) (3, 23, 
24). Treatment with MTX has also been used successfully in murine models of 
inflammatory arthritis, including collagen-induced arthritis and MRL-lpr/lpr mice (25, 26). 
The mechanism by which MTX alleviates arthritis has been extensively studied, but remains 
controversial. In some models, MTX has been shown to inhibit inflammation by increasing 
endogenous adenosine concentrations and altering the production of inflammatory cytokines 
(27, 28). Other studies have suggested that MTX leads to decreased cell proliferation and 
increased apoptosis by decreasing polyamine production and increasing intracellular reactive 
oxygen species (ROS) levels (29). Finally, MTX is a folate antagonist and therefore has also 
been proposed to inhibit arthritis through its anti-proliferative effects.(30)
Based on its anti-proliferative and anti-inflammatory properties, MTX is thought to act on 
the effector phase of the response (27, 28). In contrast, our previous data showed that 1MT 
inhibited arthritis development when administered during the initiation of the autoimmune 
response, but was ineffective once the inflammatory response was underway (7). Here, we 
use the K/BxN model to test the hypothesis that combining 1MT with MTX therapy will 
target both the initiation phase (1MT) and chronic inflammatory phase (MTX) of the 
autoimmune response. Our data show that the combination of a low dose of MTX with 1MT 
is significantly more effective than either treatment alone at delaying the onset and 
alleviating the severity of joint inflammation and suggest that pharmacological inhibition of 
IDO with 1MT is a potential candidate for use in combination with MTX in the treatment of 
RA.
Methods
Mice
KRN TCR Tg mice (31) and IDO1 deficient (IDO−/−) mice (32) on a C57BL/6 background 
have been described. NOD mice were purchased from Jackson laboratories. To obtain 
arthritic mice, KRN Tg C57BL/6 mice were crossed with NOD mice yielding KRN 
(C57BL/6 x NOD)F1 mice designated K/BxN or C57BL/6 mice expressing the I-Ag7 MHC 
Class II molecule, designated KRN B6.g7. IDO−/− arthritic mice were generated by breeding 
KRN IDO−/− C57BL/6 mice expressing the I-Ag7 MHC Class II molecule (KRN/IDO−/− 
B6.g7). All mice were bred and housed under specific pathogen free conditions in the 
animal facility at the Lankenau Institute for Medical Research. Studies were performed in 
accordance with National Institute of Health and Association for Assessment and 
Accreditation of Laboratory Animal Care guidelines with approval from the LIMR 
Institutional Animal Care and Use Committee.
Administration of 1MT, MTX, and inhibitors
Mice were given 400 mg/kg/dose (100µl total volume) of D/L-1MT (Sigma) diluted in 
Methocel/Tween (0.5% methylcellulose (w/v), 0.5% Tween 80 (v/v) in water) twice daily by 
oral gavage (p.o.); (33) 1, 10, or 25 mg/kg/dose (100µl total volume) of MTX (Hannah 
Pharmaceuticals) diluted in Methocel/Tween weekly p.o.; 0.5mg/kg IB-MECA (Sigma) 
diluted in saline daily i.p.; 10mg/kg theophylline (Sigma) diluted in Methocel/Tween daily 
p.o.; 1% difluoromethylornithine (DFM0; ILEX oncology) in the drinking water; 1 or 
Pigott et al. Page 3
Autoimmunity. Author manuscript; available in PMC 2015 September 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
25mg/kg folinic acid (Sigma) diluted in Methocel/Tween daily p.o.; or a combination of 
1MT, MTX, and the inhibitors. Folinic acid and MTX were administered 8hr apart to avoid 
interference with their uptake (28, 30). Control mice were given an equal volume of carrier 
alone (Methocel/Tween).
Arthritis incidence
The two rear ankles of K/BxN mice were measured starting at weaning (3 wk of age). 
Measurement of ankle thickness was made above the footpad axially across the ankle joint 
using a Fowler Metric Pocket Thickness Gauge. Ankle thickness was rounded off to the 
nearest 0.05mm. At the termination of the experiment, ankles were fixed in 10% buffered 
formalin for 48h, decalcified in 14% EDTA for 2wks, embedded in paraffin, sectioned, and 
stained with H&E. Histology sections were imaged using a Zeiss Axioplan microscope with 
a Zeiss Plan-Apochromat 10x/0.32 objective and Zeiss AxioCam HRC camera using 
AxioVision 4.7.1 software. The images were then processed using Adobe Photoshop CS2 
software.
ELISpot Assay
LN cells were plated at 4 × 105 cells per well and diluted serially 1:4 in Multiscreen HA 
mixed cellulose ester membrane plates (Millipore) coated with GPI-his (5µg/ml). The cells 
were incubated on the Ag-coated plates for 4h at 37°C. The Ig secreted by the plated cells 
was detected by Alkaline Phosphatase-conjugated goat anti-mouse total Ig secondary Ab 
(Southern Biotechnology Associates) and visualized using NBT/BCIP substrate (nitroblue 
tetrazolium / 5-bromo-4-chloro-3-indolyl phosphate; Sigma).
ELISA Assay
Serum samples were plated at an initial dilution of 1:100 and diluted serially 1:5 in Immulon 
II plates coated with GPI-his (5µg/ml). Recombinant GPI-his protein was generated and 
purified as described previously (34). Donkey anti-mouse total Ig- HRP (Jackson 
Immunoresearch) was used as a secondary Ab. Ab was detected using ABTS (2,2'-Azinobis 
[3-ethylbenzothiazoline-6-sulfonic acid]-diammonium salt) substrate (Fisher). The serum 
titer was defined as the reciprocal of the last dilution that gave an OD>3x background.
Cytokine Secretion
Cells from the draining lymph nodes (LNs) of MTX alone or MTX + 1MT treated K/BxN 
mice were harvested and cultured in PMA (50 ng/ml) + ionomycin (500 ng/ml) for 24h. As a 
negative control, cells were cultured in media alone. The supernatants were then harvested 
and analyzed for the levels of IL-4, IL-5, IL-6, IL-9, IL-10, IL-13, IL-17, MIP-1α, MIP-1β, 
RANTES, TNFα, IFNγ, and MCP-1 by cytometric bead array (BD Biosciences). The 
samples were stained according to manufacturer instructions and analyzed on a FACSCanto 
II flow cytometer (BD Biosciences) using FACSDiva software (BD Biosciences). Cytokine 
concentrations were calculated by comparing to standard curves generated using 
recombinant cytokines provided with the cytometric bead array kit and analyzed with FACS 
array analysis software (BD Biosciences). The CBA assay is a validated and commonly used 
assay to measure cytokines (35, 36); however we also confirmed the levels of two cytokines 
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(IL-6 and IL-17) in groups of 1MT and carrier-treated mice using a conventional ELISA 
assay. Within a treatment group, the levels of both IL-6 and IL-17 were similar whether 
measured by conventional ELISA or CBA. Likewise, the decrease in IL-6 seen in the 1MT-
treated group and lack of difference in IL-17 levels between carrier and 1MT treatment were 
also seen with both assays. (Supplementary Fig. 1).
Statistical Analysis
Statistical significance was determined using an unpaired Student’s t test or the Mann-
Whitney nonparametric test and Instat Software (GraphPad Software, Inc).
Results
1MT synergizes with methotrexate to inhibit arthritis in K/BxN mice
To test the hypothesis that combining 1MT and MTX would target both the initiation and 
effector phases and therefore be more effective as a co-therapeutic, K/BxN mice were 
treated with MTX with or without 1MT (D/L racemic mix) starting at 3 weeks of age, before 
the onset of arthritis (Fig. 1). The treated mice were then followed for the severity of 
arthritis by measuring inflammation in the ankles and by histological examination of the 
joints for immune cell infiltrates, synovial hyperplasia, panus formation, and cartilage and 
bone erosion. MTX was able to partially inhibit arthritis development when used 
individually at a high dose (10 or 25 mg/kg), but was ineffective at a low dose (1mg/kg, Fig. 
1a). Similarly, 1MT was also able to partially inhibit arthritis when administered as a single 
agent therapy (Fig. 1b and (7)). Because high doses of MTX are associated with severe side 
effects (28, 37), we tested the efficacy of a low dose of MTX combined with 1MT. 
Intriguingly, the combination of a low dose of MTX (which had no effect as a single agent) 
together with 1MT was significantly more effective than either treatment alone at delaying 
the onset and alleviating the severity of joint inflammation (Fig. 1b). Histological analysis 
confirmed that ankles from MTX+1MT treated animals had less inflammatory cell 
infiltrates, synovial infiltration, and cartilage damage than carrier-treated mice or those that 
received either MTX or 1MT alone (Fig. 2). In this experiment, MTX and 1MT were 
administered prophylactically, demonstrating that treatment throughout the course of disease 
can prevent arthritis development. To determine if the combination of MTX and 1MT would 
also be effective at treating established arthritis, K/BxN mice were allowed to develop 
arthritis and then treated with MTX alone, 1MT alone, or MTX + 1MT (Fig. 1c). Neither 
1MT nor a low dose of MTX affected established arthritis when administered as single 
agents. The combination of MTX and 1MT did slow the progression of arthritis, albeit not as 
effectively as when administered prior to arthritis onset (Fig. 1c). These data suggest the 
combination of MTX and 1MT is an effective strategy to inhibit both the initiation and 
effector stages of the autoimmune response as a treatment option for alleviating 
inflammatory arthritis.
IDO deficient mice are more responsive to MTX treatment
Because pharmacologic inhibitors such as 1MT may have unintended effects on other 
pathways, we used a genetic “knockout” mouse mutant of IDO. IDO deficient (IDO−/−) 
arthritic mice were generated by breeding KRN IDO−/− C57BL/6 mice expressing the I-Ag7 
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MHC Class II molecule (KRN/IDO−/− B6.g7). KRN B6.g7 mice develop arthritis with 
similar kinetics as the original K/BxN mice without the other immune complications of the 
NOD genetic background (31). As was demonstrated in the K/BxN model, treatment with a 
low dose of MTX (1mg/kg) does not inhibit the onset or severity of arthritis in KRN B6.g7 
mice (Fig. 3a). In contrast, this low dose of MTX significantly inhibited both the time of 
onset and severity of arthritis in KRN/IDO−/− B6.g7 mice (Fig. 3b). Therefore, both 
pharmacological inhibition and genetic knockout approaches demonstrate a synergistic role 
for inhibition of the IDO pathway together with MTX in the treatment of RA.
Combination of MTX and 1MT does not further inhibit autoantibody response
Our results suggest that the combination of MTX + 1MT synergizes to alleviate arthritis by 
inhibiting both the initiation (1MT) and effector (MTX) stages of the autoimmune response. 
One mechanism to explain this synergistic effect is that 1MT and MTX are acting on 
different cellular or molecular targets leading to a more effective inhibition of the overall 
autoimmune response and reduced arthritis. Arthritis in the K/BxN model has been shown to 
be dependent on B cells producing pathogenic antibodies to the glycolytic enzyme, 
glucose-6-phosphate isomerase (GPI) (19). Previously, we demonstrated that the most 
dramatic effect of 1MT treatment was on this pathogenic anti-GPI B cell response (7). 
Single agent therapy with 1MT inhibited the autoreactive B cell response, leading to lower 
serum anti-GPI Ig titers and reduced numbers of anti-GPI antibody secreting cells (ASCs) 
(Fig. 4 and ref. (7)). To determine if MTX also affects the anti-GPI B cell response and 
synergizes with 1MT to further reduce pathogenic anti-GPI Ig, the titer of serum anti-GPI Ig 
and number of anti-GPI antibody secreting cells in the dLNs was compared between mice 
treated with the combination of MTX + 1MT and control mice treated with MTX alone, 
1MT alone, or carrier (Fig. 4). Serum anti-GPI titers were reduced in mice treated with 
either 1MT or MTX alone, compared to carrier-treated mice; however, no additional 
reduction was measured in mice treated with both MTX and 1MT (Fig. 4a). Similarly, 
treatment with MTX alone and 1MT alone both reduced the number of anti-GPI ASCs 
detected in the dLNs, but the combination of MTX and 1MT provided no additional benefit 
(Fig. 4b). These data demonstrate that both MTX and 1MT are able to inhibit the pathogenic 
B cell response when used as single agents, but this does not explain their synergistic effect 
on inhibiting the overall joint inflammatory response.
MTX + 1MT combination therapy does not inhibit inflammatory cytokines
Treatment with MTX has been shown to reduce levels of the inflammatory cytokines IL-6, 
IFNγ, and TNFα in the collagen induced arthritis model (25, 27, 28) and IL-4, IL-6, IL-13, 
TNFα, IFNγ, and GM-CSF in human RA patients (38–40). Similarly, we have shown that 
levels of IL-5, IL-6, IL-10, MCP-1, TNFα, and IFNγ are reduced in arthritic mice treated 
with 1MT (7, 8). To determine if altered cytokine profiles could explain the synergistic 
effect of MTX + 1MT, the levels of a panel of cytokines in the joint draining lymph nodes 
were compared in K/BxN mice treated with 1MT alone, MTX alone, or the combination of 
MTX + 1MT (Table 1). As we showed previously, levels of IL-5, IL-6, IL-10, MCP-1, 
TNFα, and IFNγ were reduced in mice treated with 1MT alone. Mice treated with a low 
dose of MTX alone had decreased levels of IL-10, but increased levels of RANTES. Levels 
of the other cytokines tested were not significantly different from control treated mice. Mice 
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treated with the combination of MTX and 1MT did show lower levels of RANTES 
compared to MTX alone treated mice; however, the combination of MTX and 1MT did not 
show any synergistic effect compared to mice treated with 1MT alone. In fact for most 
cytokines, the beneficial effect of 1MT was lost in the MTX + 1MT group (Table 1). 
Therefore, the synergistic effect of combined MTX + 1MT treatment cannot be explained by 
a reduction in inflammatory cytokines.
MTX synergizes with 1MT by inhibition of folate metabolism
To further explore the mechanism by which 1MT synergizes with MTX, we investigated the 
potential downstream pathways targeted by MTX. The precise mechanism by which MTX 
acts to inhibit arthritis is unknown and remains controversial (27, 41). In some models, 
MTX has been shown to inhibit inflammation by increasing endogenous adenosine 
concentrations and altering the production of inflammatory cytokines (27, 28). Other studies 
have suggested that MTX leads to decreased cell proliferation and increased apoptosis by 
decreasing polyamine production and increasing intracellular reactive oxygen species (ROS) 
levels (29). Finally, MTX is a folate antagonist and therefore has also been proposed to 
inhibit arthritis through its anti-proliferative effects (30). To determine which, if any, of 
these mechanisms are responsible for the synergy between MTX and 1MT, we used a 
combination of inhibitors and agonists to probe the requirement of increased adenosine 
concentration, polyamine inhibition, and folate antagonism for MTX action.
To determine if the anti-arthritic effect of MTX was mediated by increased adenosine 
concentration, we inhibited adenosine receptors with the adenosine receptor antagonist 
theophylline in mice treated with the combination of MTX + 1MT (42). If the effect of MTX 
was due to increased adenosine release, then theophylline should block this effect and lead 
to increased arthritis in mice treated with MTX and 1MT. Treatment with theophylline alone 
had no effect on arthritis onset or progression, nor did it reverse the anti-arthritic effect when 
added to combination therapy of MTX + 1MT (Fig. 5a). Because theophylline antagonizes 
the A1, A2a, and A2b adenosine receptors, but does not affect the A3 receptor, in a second 
set of experiments, we combined 1MT with an adenosine receptor agonist (IB-MECA) to 
stimulate the A3 adenosine receptor directly (43). If adenosine signaling through the A3 
receptor was responsible for MTX’s anti-arthritic effect, then IB-MECA should be able to 
mimic MTX’s synergistic effect when combined with 1MT. Administration of IB-MECA 
alone had no effect on arthritis, nor did it mimic the synergistic anti-arthritic effect of MTX 
when combined with 1MT (Fig. 5b). Together, these data demonstrate that the synergistic 
effect of MTX and 1MT is not due to the release of the anti-inflammatory molecule 
adenosine.
To determine if MTX is acting by reducing polyamine production, we used DFMO, an 
inhibitor of ornithine decarboxylase (ODC), a critical enzyme in the polyamine synthesis 
pathway (44). K/BxN mice were treated with DFMO alone or in combination with 1MT 
(Fig. 5c). Both 1MT alone and DFMO alone delayed the onset and reduced the severity of 
arthritis. However, DFMO was not able to mimic the effect of MTX when combined with 
1MT, as the combination of DFMO + 1MT did not show an enhanced effect over either 
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agent used individually. These data suggest that polyamine inhibition is not the mechanism 
by which MTX synergizes with 1MT to alleviate arthritis in K/BxN mice.
Finally, to determine if folate antagonism was required for the action of MTX, mice were 
supplemented with folinic acid, a technique shown to partially bypass the effect of MTX in 
the antigen induced arthritis (AIA) model in rats (30). K/BxN mice were treated with the 
combination of 1MT + MTX in the presence or absence of folinic acid. Treatment with 
folinic acid alone had no effect on arthritis development. However, addition of folinic acid 
to 1MT + MTX co-therapy reversed the synergistic anti-arthritic effect, as inflammation in 
the joints from mice treated with 1MT + MTX + folinic acid approached the levels found in 
Carrier, MTX alone, or folinic acid alone treated mice (Fig. 5d). Therefore, these data 
suggest that MTX synergizes with 1MT to alleviate arthritis by antagonism of the folate 
pathway.
Discussion And Conclusions
Current therapeutic strategies to treat RA primarily focus on controlling or alleviating 
inflammation and the inflammatory mediators driving chronic disease (2–4). This includes 
MTX, the most commonly used drug in the treatment of RA (3, 23). In contrast, we have 
shown that 1MT, an inhibitor of the IDO pathway, blocks the initial stages of the 
autoimmune response underlying arthritis development in the K/BxN mouse model of RA 
(7, 8). In this study, we tested the efficacy of combining MTX with 1MT to target both the 
effector and initiation stages of the autoimmune response. Both 1MT and high doses of 
MTX were able to partially inhibit arthritis development when used individually; however 
the combination of 1MT with a low dose of MTX was significantly more effective than 
either treatment alone at delaying the onset and alleviating the severity of joint inflammation 
(Fig. 6).
Combination therapy is becoming an increasingly popular therapeutic strategy in the 
treatment of RA (45). Patients who do not experience lowered disease activity in response to 
monotherapy with a DMARD like MTX often experience better results when it is used in 
combination with another therapeutic. For example, combining MTX with therapeutics that 
target the TNFα pathway has been effective for some patients (45). In fact, the latest 
American College of Rheumatology recommendations for the use of DMARDs and 
biologics in RA include a prominent role for combination therapies early in the treatment 
process, a change from previous treatment paradigms (3). The thought is that using drugs 
that target different mechanistic aspects of the disease process will be more effective than 
monotherapies that focus on only one target. Our data suggest that 1MT, by targeting the 
initial stages of the autoimmune response, should also be considered as a potential new 
therapeutic option for combination therapy in the treatment of RA.
An additional benefit to co-therapy may be in the reduction in the dosage of the component 
drugs required for efficacy. Preclinical testing of 1MT did not reveal any side effects, even 
at saturating doses (46, 47). Likewise, results from phase I clinical trials in cancer patients 
reported that 1MT was generally well tolerated, although a small number of patients who 
had received prior immunotherapy did develop autoimmune hypophysitis (47–49). 
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Currently, 1MT is in Phase II clinical trials as a therapy for metastatic breast and prostate 
cancer and primary brain tumors (ClinicalTrials.gov identifier numbers: NCT01792050, 
NCT01560923, NCT02052648), but toxicity data has not yet been reported. In contrast to 
1MT, high doses of MTX are associated with severe side effects including liver toxicity and 
bone marrow suppression in human RA patients (28, 37). Due to these side effects, some 
patients are unable to tolerate high enough doses of MTX to achieve a clinical benefit (45). 
As such, a co-therapeutic strategy that uses 1MT to lower the dose of MTX required for 
therapeutic effectiveness would be clinically desirable.
The mechanism by which MTX inhibits arthritis is not clear. MTX, a folate antagonist, 
inhibits purine and pyrimidine synthesis, a mechanism that likely accounts for its 
effectiveness as a cancer therapeutic (50). Decreased folate metabolism has been shown in 
RA patients treated with MTX, suggesting that MTX may also inhibit arthritis through its 
anti-proliferative effects (30, 51). However, data from some preclinical models suggest 
instead that MTX inhibits inflammation by increasing endogenous adenosine concentrations 
and altering the production of inflammatory cytokines (27, 28). Still other studies suggest 
that MTX treatment leads to decreased cell proliferation and increased apoptosis by 
decreasing polyamine production and increasing intracellular reactive oxygen species (ROS) 
levels (29). B cell antibody production has also been reported to be diminished by MTX 
treatment (52, 53). In the current study, we tested each of these mechanisms and found that 
the synergistic co-therapeutic effect of MTX + 1MT did not lower inflammatory cytokine or 
autoantibody levels, nor could it be reversed by the adenosine receptor antagonist 
theophylline or be mimicked by inhibition of polyamine synthesis. However, 
supplementation with folinic acid did reverse the synergistic co-therapeutic effect, 
demonstrating that, in the K/BxN model, MTX synergizes with 1MT by blocking folate 
metabolism.
In contrast to MTX treatment, T helper and inflammatory cytokines are reduced in 1MT-
treated K/BxN mice, resulting in a dramatic reduction in both the number of autoantibody 
secreting cells and titers of autoantibody in the serum (7, 8). However, like MTX, the 
molecular mechanism by which 1MT exerts its anti-arthritic effect is not entirely clear. 
Although widely considered an IDO inhibitor, 1MT does not inhibit the IDO enzyme 
directly, rather it likely inhibits the IDO pathway (54). 1MT inhibition of the IDO pathway 
has been shown to modulate dendritic cell function, controlling the balance between effector 
and regulatory T cell populations (55–57). The IDO pathway is complex and the 
mechanisms controlling its role in other immune functions are only beginning to be 
established (10). Recent data suggests that IDO may function through tryptophan depletion 
and sufficiency signals influencing GCN2 and mTOR pathways (54).
In summary, we have identified a potential new co-therapeutic strategy for improving the 
efficacy of low dose MTX treatment in inflammatory arthritis. We show that targeting both 
the initiation and chronic inflammatory stages of the autoimmune response with 1MT and 
MTX, respectively, is an effective strategy to control disease symptoms. Our work suggests 
that targeting the IDO pathway with 1MT should be considered as an effective co-
therapeutic strategy for treating inflammatory autoimmune diseases like RA.
Pigott et al. Page 9
Autoimmunity. Author manuscript; available in PMC 2015 September 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. MTX synergizes with 1MT to inhibit arthritis development
(A) Dose-dependent inhibition of arthritis development by MTX. K/BxN mice were treated 
weekly with MTX (1, 10, or 25mg/kg) or carrier alone p.o. starting at the age of 3wk and 
followed for arthritis development. The graphs show mean ankle thickness ± SEM for n=8 
mice per treatment group pooled from two independent experiments. (B,C) Co-therapy with 
MTX + 1MT. K/BxN mice were treated with Carrier, MTX alone (1mg/kg), 1MT alone 
(400mg/kg), or MTX + 1MT starting (B) before (age 3wk) or (C) after arthritis onset (age 
4.5wk) and followed for the progression of arthritis. Arrows indicate the start of treatment. 
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The graphs show mean ankle thickness ± SEM for n=9 mice per treatment group pooled 
from two independent experiments. *p<0.05, n.s., not significant.
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Figure 2. MTX synergizes with 1MT to inhibit pathological signs of arthritis
K/BxN mice were treated with Carrier, MTX alone (1mg/kg), 1MT alone (400mg/kg), or 
MTX + 1MT starting at the age of 3wk. Ankles were harvested at the age of 6wk, sectioned 
and stained with hematoxylin and eosin. Images show the metatarsal joint from 
representative sections from a total of 9 mice for each treatment group. Scale bar = 100µm.
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Figure 3. MTX inhibits arthritis in IDO ko mice
(A) KRN B6.g7 (IDO wt) and (B) KRN IDO ko B6.g7 (IDO ko) mice were treated with 
MTX (1mg/kg) or carrier alone starting at the age of 3wk and followed for the development 
of arthritis. The graphs show mean ankle thickness ± SEM for n=9 IDO wt and n=6 IDO ko 
mice per treatment group pooled from two independent experiments. *p<0.05, n.s., not 
significant.
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Figure 4. MTX and 1MT do not synergize to further inhibit autoantibody production
K/BxN mice were treated with Carrier, MTX alone (1mg/kg), 1MT alone (400mg/kg), or 
MTX + 1MT from 3–6wk of age. (A) Serum anti-GPI Ig titers were measured using an 
ELISA assay. The graph shows the mean titer ± SEM from n=16 Carrier, n=10 1MT, n=14 
MTX, and n=14 MTX+1MT treated mice, pooled from 3 independent experiments. (B) 
Antibody Secreting Cells (ASCs) from the joint draining LN were measured using an 
ELISpot assay. The graph represents the mean number of ASCs ± SEM from n=13 Carrier, 
n=10 1MT, n=18 MTX, and n=14 MTX+1MT treated mice, pooled from 3 independent 
experiments. *p<0.05, **p<0.01, n.s., not significant.
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Figure 5. MTX synergizes with 1MT by inhibition of folate metabolism
K/BxN mice were treated with Carrier, MTX alone (1mg/kg), 1MT alone (400mg/kg), or 
MTX + 1MT from 3–6wk of age. To determine if the synergistic effect of 1MT + MTX was 
due to increased adenosine release, mice were treated with 1MT and MTX in combination 
with (A) the adenosine receptor A1, A2a, and A2b antagonist theophylline (10mg/kg, p.o.), 
n=10 mice per treatment group, or (B) the adenosine receptor A3 agonist IB-MECA 
(0.5mg/kg, i.p.), n=8 mice per treatment group. (C) To determine if inhibition of polyamine 
synthesis could mimic the effect of MTX, mice were treated with 1MT together with the 
ODC inhibitor DMFO (1% in drinking water), n=9 mice per treatment group. (D) To test 
whether inhibition of folate metabolism was responsible for the synergistic effect of 1MT + 
MTX, 1MT + MTX treatment was supplemented with folinic acid (25mg/kg, p.o.), n=10 
mice per treatment group. The graphs show mean ankle thickness ± SEM for the indicated 
number of mice per treatment group pooled from two independent experiments each. 
*p<0.05, n.s., not significant.
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Figure 6. Impact of 1MT and MTX on autoimmune response leading to arthritis
Arthritis in the K/BxN model can be divided into two stages (1) an initiation stage that is 
dependent on autoreactive B and T cells and (2) an effector stage that is triggered by 
immune complexes and inflammatory cytokines and dependent on macrophages, mast cells, 
and neutrophils. 1MT treatment impacts the initiation stage by inhibiting the differentiation 
of autoreactive B cells into antibody secreting cells (ASCs) and reducing the levels of 
several T helper and inflammatory cytokines. In contrast, MTX treatment, through a folate-
dependent mechanism, primarily affects the effector stage. By targeting both the initiation 
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and effector stages of the response, cotreatment with 1MT and MTX is more effective than 
either agent alone at delaying the onset and alleviating the severity of joint inflammation.
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Table 1
MTX and 1MT do not synergize to inhibit inflammatory cytokine production
K/BxN mice were treated with Carrier, MTX alone (1mg/kg), 1MT alone (400mg/kg), or MTX + 1MT from 
3–6wk of age. At 6wk, cells from the joint dLNs (popliteal, axillary, and brachial LNs) were harvested and 
cultured overnight in media alone or PMA (50ng/ml) + ionomycin (500ng/ml). Cytokines were measured in 
culture supernatants by cytometric bead array. Table shows the mean concentration ± SEM from n=20 Carrier, 
n=13 1MT, n=14 MTX, and n=12 MTX+1MT treated mice, pooled from 3 independent experiments.
Cytokine
(pg/ml)
Carrier 1MT MTX MTX+1MT
IL-4 2 ± 1 0 ± 0 5 ± 3 4 ± 3
IL-5 77 ± 9 46 ± 7* 117 ± 24 102 ± 13
IL-6 43 ± 3 27 ± 5* 39 ± 2 37 ± 5
IL-9 20 ± 4 21 ± 5 16 ± 5 20 ± 7
IL-10 144 ± 22 75 ± 17* 51 ± 15* 59 ± 19*
IL-13 109 ± 12 87 ± 18 174 ± 35 154 ± 22
IL-17 895 ± 140 709 ± 284 1061 ± 189 1226 ± 267
IFNγ 6107 ± 370 4526 ± 727* 5731 ± 650 5999 ± 871
MCP-1 159 ± 13 104 ± 13* 156 ± 19 144 ± 17
MIP-1α 662 ± 16 650 ± 55 655 ± 17 630 ± 16
MIP-1β 160 ± 6 175 ± 15 161 ± 6 153 ± 5
RANTES 616 ± 38 551 ± 89 745 ± 37 629 ± 45
TNFα 391 ± 35 224 ± 55* 371 ± 29 364 ± 42
*p<0.05
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